Galera Therapeutics, Inc. 8-K

What Happened
Galera Therapeutics, Inc. (GRTX) filed an 8-K on May 15, 2026 reporting that stockholders approved two charter amendments at the Annual Meeting on May 8, 2026. On May 11, 2026 the company filed a Certificate of Amendment to increase authorized common shares from 200 million to 400 million. On May 12, 2026 it filed a second Certificate of Amendment to add a stockholder right to act by written consent, and the Board adopted Amended and Restated Bylaws (effective May 12, 2026) implementing procedures for written consents.

Key Details

• Authorized common stock increased from 200,000,000 shares to 400,000,000 shares (Stock Increase Charter Amendment).
• Written Consent Charter Amendment filed May 12, 2026 gives stockholders the ability to act by written consent (and related bylaws were adopted the same day).
• Both amendments were approved by stockholders at the Annual Meeting on May 8, 2026.
• The full text of the amendments and Amended and Restated Bylaws are filed as Exhibits 3.1, 3.2 and 3.3 to the 8-K.

Why It Matters
Increasing authorized shares expands the number of shares the company may issue in the future (which could affect dilution if and when new shares are issued). Adding a written-consent right lets shareholders take certain corporate actions without waiting for a formal shareholder meeting, changing how corporate decisions can be made. The filing does not report any immediate issuance of new shares — it records changes to the charter and bylaws that enable future actions.